Jane Street
VTGN icon

Jane Street’s VistaGen Therapeutics VTGN Stock Holding History

Jane Street’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Buy
76,500
+53,300
+230% +$32.2K ﹤0.01% 11240
2026
Q1 		$13.3K Buy
+23,200
New +$14.1K ﹤0.01% 11274
2025
Q4 		– Sell
-14,500
Closed -$51.5K – 12523
2025
Q3 		$51.5K Buy
+14,500
New +$43.3K ﹤0.01% 10345

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jane Street's VTGN Position: Q2 2026 in Review

Jane Street reduced its VistaGen Therapeutics (VTGN) stake by 40% in Q2 2026, selling an estimated $65.1K and leaving 164,827 shares worth $37.3K. The position accounts for ﹤0.01% of the portfolio, ranked #11036.

Jane Street first reported a position in VTGN in Q1 2019 and has held it in 13 quarters since. The position peaked at $1.07M in Q3 2025. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Jane Street held 164,827 shares of VistaGen Therapeutics worth $37.3K as of Q2 2026.
  • Jane Street sold 107,984 VistaGen Therapeutics shares in Q2 2026, an estimated $65.1K.
  • VistaGen Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #11036 holding.
  • Jane Street first reported a position in VistaGen Therapeutics in Q1 2019 and has held it in 13 quarters since.
  • Jane Street's VistaGen Therapeutics position peaked at $1.07M in Q3 2025.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.